US · CPRX
Catalyst Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Coral Gables, FL 33134
- Website
- catalystpharma.com
Price · as of 2025-12-31
$28.74
Market cap 2.84B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $64.64 | +124.91% |
| Intrinsic Value(DCF) | $69.33 | +141.23% |
| Graham-Dodd Method(GD) | $16.57 | -42.36% |
| Graham Formula(GF) | $47.44 | +65.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $1.12 | $30.51 | |||
| 2012 | $0.48 | ||||
| 2013 | $2.17 | ||||
| 2014 | $4.18 | ||||
| 2015 | $1.22 | ||||
| 2016 | $1.11 | ||||
| 2017 | $3.23 | ||||
| 2018 | $2.86 | $0.12 | $0.00 | ||
| 2019 | $3.95 | $3,135.54 | $1.48 | $2.40 | $6,032.92 |
| 2020 | $3.89 | $34.29 | $34.10 | $5.26 | $17.25 |
| 2021 | $7.58 | $40.99 | $41.96 | $3.91 | $9.75 |
| 2022 | $14.64 | $63.29 | $53.75 | $6.92 | $46.51 |
| 2023 | $16.25 | $70.57 | $1,617.75 | $7.01 | $60.73 |
| 2024 | $21.96 | $60.49 | $437.56 | $13.06 | $42.22 |
| 2025 | $23.88 | $64.64 | $395.24 | $16.57 | $47.44 |
AI valuation
Our deep-learning model estimates Catalyst Pharmaceuticals, Inc.'s (CPRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $64.64
- Current price
- $28.74
- AI upside
- +124.91%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$69.33
+141.23% upside
Graham-Dodd
$16.57
-42.36% upside
Graham Formula
$47.44
+65.07% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CPRX | Catalyst Pharmaceuticals,… | $28.74 | 2.84B | +125% | +141% | -42% | +65% | 13.63 | 3.06 | 4.96 | 6.90 | 48.24 | 3.55 | 85.19% | 43.77% | 36.39% | 25.49% | 84.59% | 21.92% | 0.00 | — | 6.08 | 5.68 | -2.20 | 2824.00% | 1978.00% | -1281.00% | 7.14% | 1.42 | 90.56% | 0.00% | 0.00% | 7.46% | 8.59 | 10.61 | 3.76 | 14.42 |
| ADPT | Adaptive Biotechnologies … | $16.02 | 2.46B | +132% | +239% | — | — | -41.11 | 11.18 | 8.83 | -83.74 | — | 24.93 | 74.24% | -20.62% | -21.48% | -28.23% | -33.39% | -11.31% | 1.28 | -4.85 | 3.34 | 3.08 | -7.04 | -6389.00% | 5477.00% | -5050.00% | -2.00% | -0.51 | -28.61% | 0.00% | 0.00% | 0.00% | -43.75 | -51.06 | 9.02 | 2.04 |
| AGIO | Agios Pharmaceuticals, In… | $30.23 | 1.77B | -31% | +212% | — | — | -4.10 | 1.42 | 31.33 | -1.93 | — | 1.42 | 88.26% | -873.87% | -764.01% | -30.20% | -85.25% | -27.89% | 0.05 | — | 11.46 | 10.52 | 0.06 | -16117.00% | 4803.00% | -364.00% | -22.29% | -4.54 | -68.29% | 0.00% | 0.00% | 0.46% | -1.91 | -2.39 | 16.67 | 8.79 |
| APLS | Apellis Pharmaceuticals, … | $20.96 | 2.68B | +129% | +661% | -82% | -70% | 116.52 | 7.05 | 2.60 | 37.53 | — | 7.05 | 89.81% | 5.52% | 2.23% | 7.48% | 15.34% | 2.28% | 1.31 | 1.25 | 3.14 | 2.58 | 0.26 | -11125.00% | 2846.00% | -15100.00% | 1.73% | 0.14 | 13.42% | 0.00% | 0.00% | 1.53% | 47.40 | 58.37 | 2.62 | 0.17 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| CDTX | Cidara Therapeutics, Inc. | $221.38 | 5.61B | -67% | -96% | — | +934% | -0.88 | 0.92 | 117.83 | 0.20 | -0.22 | 0.92 | -6557.49% | -13811.92% | -13319.76% | -218.99% | 567.59% | -120.52% | 0.02 | — | 4.25 | 3.86 | 1.06 | 40952.00% | -9800.00% | 67021.00% | -117.59% | -3.56 | 569.40% | 0.00% | 0.00% | 103.41% | 0.20 | 0.20 | -28.25 | -4.03 |
| IDYA | IDEAYA Biosciences, Inc. | $32.20 | 2.83B | +1,323% | +773% | -84% | — | -25.71 | 2.86 | 13.37 | -14.94 | — | 2.86 | 97.90% | -72.84% | -51.99% | -10.92% | -39.17% | -10.18% | 0.03 | — | 11.34 | 10.87 | 0.55 | -6190.00% | 302443.00% | -7078.00% | -2.51% | -1.21 | -18.06% | 0.00% | 0.00% | 0.67% | -14.51 | -31.47 | 10.57 | 19.76 |
| KNSA | Kiniksa Pharmaceuticals, … | $44.49 | 3.3B | +56% | +8,673% | -74% | +17% | -79.02 | 6.01 | 5.04 | 33.27 | — | 6.18 | 54.63% | 11.40% | 8.71% | -8.59% | 27.89% | -6.43% | 0.02 | — | 3.79 | 3.09 | -1.73 | -22500.00% | 6009.00% | 0.00% | 0.74% | 0.18 | 13.82% | 0.00% | 0.00% | 0.23% | 38.96 | 118.40 | 4.44 | 11.43 |
| MLYS | Mineralys Therapeutics, I… | $29.26 | 1.94B | — | — | — | — | -2.87 | 2.67 | — | -1.62 | -3.42 | 2.67 | 0.00% | — | — | -82.24% | 16423.64% | -77.72% | 0.00 | — | 14.02 | 13.53 | 0.59 | 8392.00% | — | 10501.00% | -32.59% | -11.36 | 14204.87% | 0.00% | 0.00% | 12.69% | -1.62 | -1.88 | — | 16.89 |
| RXRX | Recursion Pharmaceuticals… | $3.67 | 1.47B | +586% | +721% | — | — | -2.52 | 1.44 | 21.75 | -1.71 | — | 2.47 | -61.96% | -867.87% | -863.35% | -59.54% | -127.75% | -44.12% | 0.07 | -358.08 | 5.50 | 5.20 | 1.19 | -1479.00% | 2692.00% | 145.00% | -23.29% | -2.52 | -74.58% | 0.00% | 0.00% | 11.05% | -1.48 | -2.53 | 12.84 | 0.01 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
- CEO
- Richard John Daly
- Employees
- 181
- Beta
- 0.73
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($69.33 ÷ $28.74) − 1 = +141.23% (DCF, example).